1. Abouk, R., Grosse, S. D., Ailes, E. C., & Oster, M. E. (2017). Association of US state implementation of newborn screening policies for critical congenital heart disease with early infant cardiac deaths. Journal of the American Medical Association, 318(21), 2111–2118.
2. Allen, H. D., Driscoll, D. J., Shaddy, R. E., & Feltes, T. F. (2013). Moss & Adams' heart disease in infants, children, and adolescents: Including the fetus and young adult. Lippincott Williams & Wilkins.
3. Altamura, A. C., Moliterno, D., Paletta, S., Maffini, M., Mauri, M. C., & Bareggi, S. (2013). Understanding the pharmacokinetics of anxiolytic drugs. Expert Opinion on Drug Metabolism & Toxicology, 9(4), 423–440.
4. Barry, C. L., Martin, A., & Busch, S. H. (2012). ADHD medication use following FDA risk warnings. The Journal of Mental Health Policy and Economics, 15(3), 119.
5. Bean Jaworski, J. L., Flynn, T., Burnham, N., Chittams, J. L., Sammarco, T., Gerdes, M., … Zackai, E. H. (2017). Rates of autism and potential risk factors in children with congenital heart defects. Congenital Heart Disease, 12(4), 421–429. https://doi.org/10.1111/chd.12461